Re:FDA grants Breakthrough Therapy designation to MDMA for t...
by ohbleek on Monday August 28, 2017 @08:58PM
(#15121396)
I personally worked on developing the Investigative Brochure for procedure in preparation for the Phase 3 clinical trials at MAPS. The concerns regarding neurotoxicity are mitigated through dosage and low frequency. The ideal treatment plan would only include one session with a therapist in which the patient is given a dosage of MDMA, over a six month period. During that session it's possible for the patient to receive a supplemental dosage dependent on the needs of the patient and the recommendations of the therapist. This can be adjusted and in previous trials some patients have had 2 MDMA-assisted sessions over 6 months but it is not common so far and other options are being considered.
[ Parent
| on HN ]
Re:FDA grants Breakthrough Therapy designation to MDMA for t...
by fitzroy on Tuesday August 29, 2017 @02:32AM
(#15122510)
Can you comment at all about how the MDMA therapy session is conducted and/or structured, compared to a normal 50 minute session?
Re:FDA grants Breakthrough Therapy designation to MDMA for t...
by catshirt on Tuesday August 29, 2017 @09:19AM
(#15124034)
Rick Doblin, founder of MAPS, talks a bit about this in his interview with Duncan Trussel: http://www.duncantrussell.com/episodes/2016/7/18/rick-doblin
(i'd imagine this information is available elsewhere, this is just the instance i happened to come across myself...)
Re:FDA grants Breakthrough Therapy designation to MDMA for t...
by anythingnonidin on Tuesday August 29, 2017 @03:36PM
(#15126995)